Resveratrol does not reduce CVD risk, prolong life e A statistical point of view
To the Editor:
I read the paper "Resveratrol Levels and All-Cause Mortality in Older Community-Dwelling Adults" by Semba et al. (JAMA Intern. Med. 2014; 174(7):1077e1084) [1] , where the authors want to determine whether resveratrol levels achieved with diet are associated with inflammation, cancer, cardiovascular disease, and mortality in humans. In this paper, the authors concluded as "In older community-dwelling adults, total urinary resveratrol metabolite concentration was not associated with inflammatory markers, cardiovascular disease, or cancer or predictive of all-cause mortality." I also read a review "Resveratrol Does Not Reduce CVD Risk, Prolong Life". It says "In terms of patient recommendations, Semba offered a simple one, that patients can continue to enjoy red wine in moderation, but it isn't going to help them live longer or protect them against heart disease and cancer."
This research is very interesting. However, from a statistical point of view, I do not think Dr. Semba et al. can have that strong statement "In older community-dwelling adults, total urinary resveratrol metabolite concentration was not associated with inflammatory markers, cardiovascular disease, or cancer or predictive of all-cause mortality". Based on the analysis in the paper, it is statistically wrong to have this strong statement or give the recommendation "patients can continue to enjoy red wine in moderation, but it isn't going to help them live longer or protect them against heart disease and cancer". When P-value is small (usually < 0.05), we can say we have the evidence to reject the null hypothesis and have the conclusion of association. But when the P-value is large, we can only say we do not have the evidence to reject the null hypothesis, but we cannot say we have proved the null hypothesis (no association). For example, when a study does not have enough sample size, we can have large P-value, even wrong trend when the association is real. Unfortunately, there is no sample size or power calculation in this paper. However, in the discussion section, the authors mentioned "a much larger sample size would be needed to detect the association". Overall, I think the authors have made a fundamental statistical error in selling their findings.
Can we prove no association? Statistically, it can never be done. With a large sample size (tending to infinity), one can always find a very small effect size (tending to 0) to show a statistically nonsignificant result. However, is this small effect size clinically important? We can prove that not having Resveratrol is clinical equivalence to having Resveratrol or not having Resveratrol is Not CLINICALLY SIGNIFICANTLY worse than having Resveratrol.
Suggests: the authors can provide a one-sided 95% CI for the HR. Based on the number provided in the paper, the CI is (0, 1.11), which implies that the study can rule out a benefit of 10% or more reduction in mortality for having an elevated resveratrol level. Therefore, the study suggests that high resveratrol level is unlikely to be associated with 10% or more reduction in mortality. A larger sample size can provide a more accurate estimate.
